

Announcement

European School of Oncology Award for Outstanding Research in Cancer Chemotherapy



The European School of Oncology announces an award of \$15,000 for research in cancer chemotherapy. The purpose of the award is to recognize outstanding achievement in cancer chemotherapy research and to provide financial assistance to candidates working in this field.

Eligibility

This award is open to European Oncologists under the age of 35 working in the field of clinical or experimental cancer chemotherapy.

Institute's Director or Departmental Head, a brief resume of the candidate's career and copies of all candidate's publications.

Applications

Directors of institutes or Departmental Heads are invited to submit names of applicants on behalf of proposed candidates to the ESO Award Selection Committee, Via Venezian 1, 20133 Milano, Italy, by December 30, 1984. Proposal should consist of a letter of endorsement of the candidate by the

Award Lecture

Selection of the award recipient will be made by the ESO Award Selection Committee at the end of March 1985. Presentation of the award will be made at the 3rd ECCO meeting, June 1985, in Stockholm and will be followed by a plenary lecture by the award recipient to the ECCO Congress.



This award is made possible by an educational grant from Lederle Laboratories, A Division of American Cyanamid Company Wayne, New Jersey, USA

European School of Oncology postgraduate courses in medical oncology 1984/1985

1984 Final course

3-6 October, Pain treatment in oncology.
Chairman: V. Ventafridda (Milan)

1985


18-23 March, Head and neck tumors, Chairman: G.B. Snow (NL)
22-27 April, Chest tumors, Chairman: H. Hansen (DK)
13-18 May, Occupational tumors, Chairman: L. Tomatis (IARC)
27 May-1 June, Genito-urinary tract tumors, Chairman: L. Denis (B)
27-29 June, Nutrition and cancer, Chairman: F. Bozzetti (I)
8-14 July, Medical oncology, Chairman: H.M. Pinedo (NL)
30 Sept.-5 Oct., Breast cancer, Chairman: U. Veronesi (I)

For information, write:

Secretariat:
E.S.O. European School of Oncology
Via Venezian, 1-20133 Milano-Italy

This publication is available in microform.

1981, 2, 100, 150
1981, 10, 150
1981, 10, 150
UNIVERSITY MICROFILMS INTERNATIONAL



University Microfilms International

Please send additional information for _____
(name of publication)

Name _____

Institution _____

Street _____

City _____

State _____ Zip _____

300 North Zeeb Road
Dept. P.R.
Ann Arbor, Mi. 48106
U.S.A.

30-32 Mortimer Street
Dept. P.R.
London W1N 7RA
England




THE BLUNT TRUTH

FOR CONTINUOUS DOSING, CONVENIENCE, AND RESULTS... ALZET[®] OSMOTIC PUMPS DELIVER:

CONTINUOUS DOSING

Alzet Osmotic Pumps offer the choice of 1-4 weeks of delivery, night and day, for continuous presence of even the shortest half-life agent.



CONVENIENCE

Implantation can be completed in less than one minute. It is easily mastered. ALZA Corporation loans free of charge a videocassette showing subcutaneous and other implantation procedures.

RESULTS

Multiday infusions insure that you measure the fully-developed actions of your test agent in the steady-state. Single-dose studies are useful, but the actions of many agents are far from fully developed by a single dose. The Alzet Osmotic Pumps have demonstrated their ability to deliver good results in nearly a thousand publications.

NEW APPLICATIONS

Alzet Osmotic Pumps are now being used for direct tissue microperfusion with labelled amino acids and other precursors to demonstrate *in vivo* biosynthesis. Another new application of

the pumps is localized drug delivery to the rat kidney via renal arterial infusion.

To place an order, call toll-free 800-227-9953. In California, Alaska & Hawaii call collect (415) 494-5067. For more information mail the coupon below.

alzet
OSMOTIC PUMPS

Please send me information on the Alzet Osmotic Pumps. CR-10-84

Name _____

Affiliation _____

Address _____

City _____ State _____ Zip _____

Mail to: ALZA Corporation
Dept. Y, P.O. Box 10950
950 Page Mill Rd.
Palo Alto, CA 94303-0802



More people have survived cancer than
now live in the City of Los Angeles.

We are winning.

Please support the

 **AMERICAN CANCER SOCIETY®**